1. Academic Validation
  2. Zinc pyrithione functions as a small-molecule STING agonist to exert antitumor immunotherapy effects

Zinc pyrithione functions as a small-molecule STING agonist to exert antitumor immunotherapy effects

  • Acta Pharmacol Sin. 2025 Oct 17. doi: 10.1038/s41401-025-01674-9.
Man Zhao # 1 2 Zu-Yi Jin # 1 Wei-Zhen Fan # 1 Peng-Fei Qiang 1 Zhi-Hua Zheng 1 Guo-Feng Li 3 Liang Hong 4 Min Li 5
Affiliations

Affiliations

  • 1 State Key Laboratory of Anti-infective Drug Discovery and Development, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
  • 2 School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518060, China.
  • 3 School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518060, China. liguofeng@szu.edu.cn.
  • 4 State Key Laboratory of Anti-infective Drug Discovery and Development, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. hongliang@sysu.edu.cn.
  • 5 State Key Laboratory of Anti-infective Drug Discovery and Development, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. limin65@mail.sysu.edu.cn.
  • # Contributed equally.
Abstract

The stimulator of interferon genes (STING) is a crucial pattern recognition receptor that activates innate immunity, particularly in response to pathogen Infection and various stimuli. Notably, activation of STING exhibits remarkable potential in enhancing anti-tumor immunity, underscoring the significance of discovering STING small molecule agonists. Recently, zinc pyrithione (ZPT), a marketed Antifungal small molecule, has been reported to possess anti-tumor activity through various mechanisms. Our preliminary screening of STING agonists revealed that ZPT could significantly induce STING activation. In this study, we investigated whether ZPT exerted Anticancer effects as a small molecule activator of STING. We showed that ZPT bound to the STING protein in vitro with KD value of 2.72 μM, and ZPT (1-16 μM) dose-dependently activated the STING-TBK1-IRF3 signaling axis in THP-1 cells. In MC38 tumor-bearing wild-type C57BL/6 mice with normal immune systems, administration of ZPT (5, 10, or 20 mg/kg, i.p., every two days for 14 days) dose-dependently inhibited the tumor growth, activated CD45+, CD3+, and CD8+ T cells in both tumors and spleens, and significantly elevated IL-6 secretion in the peripheral blood. These results highlight the potential of ZPT as an immunotherapeutic agent targeting STING.

Figures
Products